Debu Tripathy, MD, Co-Leader, Women's Cancer Program, Norris Comprehensive Cancer Center, University of Southern California, describes intratumoral heterogeneity in patients with breast cancer.
Debu Tripathy, MD, Co-Leader, Women's Cancer Program, Norris Comprehensive Cancer Center, University of Southern California, describes intratumoral heterogeneity in patients with breast cancer.
Previously, tumors and their metastases were thought to be clonal and it was unknown that they could change over time as there were limited ways to analyze a tumor: with proteins, large segments of DNA, and DNA deletions.
Today, with the development of more discriminating techniques such as whole genome sequencing, protein arrays, and RNA arrays, oncologists are observing intratumoral heterogeneity. This notion makes sense, Tripathy says, as a tumor is essentially a microecosystem with cells vying to survive. It has become routine practice to obtain a biopsy of a tumor's metastases to confirm that it is cancerous and also to recheck biomarkers.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
NGS and ctDNA Considered in Advanced Breast Cancer After Progression
May 3rd 2024During a Case-Based Roundtable® event, Ruth M. O'Regan, MD, led a discussion on whether to order next-generation sequencing and/or circulating tumor DNA testing for a patient with hormone receptor–positive breast cancer after progression in the first article of a 2-part series.
Read More